Do analysts rate GRDX or ROC?

Rank One Computing has a consensus target price of $9.00, indicating a potential upside of 111.27%. Given Rank One Computing's stronger consensus rating and higher probable upside, analysts clearly believe Rank One Computing is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Rank One Computing 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GRDX or ROC more profitable?

Rank One Computing's return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -47.34% -16.07% Rank One Computing N/A N/A N/A

Do analysts recommend GRDX or THRY?

Thryv has a consensus target price of $8.50, suggesting a potential upside of 327.14%. Given Thryv's stronger consensus rating and higher possible upside, analysts plainly believe Thryv is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Thryv 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Do analysts prefer GRDX or SSTI?

SoundThinking has a consensus target price of $10.83, indicating a potential upside of 83.00%. Given SoundThinking's stronger consensus rating and higher possible upside, analysts clearly believe SoundThinking is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SoundThinking 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend BTCS or GRDX?

BTCS presently has a consensus target price of $5.00, suggesting a potential upside of 290.63%. Given BTCS's stronger consensus rating and higher possible upside, equities analysts clearly believe BTCS is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BTCS 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend AISP or GRDX?

Airship AI presently has a consensus price target of $6.50, suggesting a potential upside of 245.74%. Given Airship AI's stronger consensus rating and higher possible upside, analysts clearly believe Airship AI is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Airship AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Entero Therapeutics (GRDX) Competitors

$3.02 +0.05 (+1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$3.04 +0.02 (+0.66%)

As of 04:10 PM Eastern

Compare

GRDX vs. ROC, THRY, SSTI, BTCS, and AISP

Should you buy Entero Therapeutics stock or one of its competitors? Entero Therapeutics's main competitors and comparable companies include Rank One Computing (ROC), Thryv (THRY), SoundThinking (SSTI), BTCS (BTCS), and Airship AI (AISP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Entero Therapeutics compare to Rank One Computing?

Entero Therapeutics (NASDAQ:GRDX) and Rank One Computing (NASDAQ:ROC) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

12.3% of Entero Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Rank One Computing's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-47.34%	-16.07%
Rank One Computing	N/A	N/A	N/A

In the previous week, Entero Therapeutics and Entero Therapeutics both had 2 articles in the media. Entero Therapeutics' average media sentiment score of 1.43 beat Rank One Computing's score of 0.93 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entero Therapeutics	Positive
Rank One Computing	Positive

Rank One Computing has higher revenue and earnings than Entero Therapeutics. Rank One Computing is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	538.32	-$6.39M	-$1.90	N/A
Rank One Computing	$16.98M	4.79	-$2.68M	-$0.22	N/A

Rank One Computing has a consensus target price of $9.00, indicating a potential upside of 111.27%. Given Rank One Computing's stronger consensus rating and higher probable upside, analysts clearly believe Rank One Computing is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rank One Computing	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Rank One Computing beats Entero Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to Thryv?

Entero Therapeutics (NASDAQ:GRDX) and Thryv (NASDAQ:THRY) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Entero Therapeutics has a net margin of 0.00% compared to Thryv's net margin of -2.27%. Thryv's return on equity of -7.36% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-47.34%	-16.07%
Thryv	-2.27%	-7.36%	-2.36%

Entero Therapeutics has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market. Comparatively, Thryv has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 96.4% of Thryv shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Thryv shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Thryv has a consensus target price of $8.50, suggesting a potential upside of 327.14%. Given Thryv's stronger consensus rating and higher possible upside, analysts plainly believe Thryv is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Thryv	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Thryv has higher revenue and earnings than Entero Therapeutics. Thryv is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	538.32	-$6.39M	-$1.90	N/A
Thryv	$785.02M	0.11	$310K	-$0.37	N/A

In the previous week, Thryv had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 6 mentions for Thryv and 2 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.43 beat Thryv's score of 0.51 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entero Therapeutics	Positive
Thryv	Positive

Summary

Thryv beats Entero Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Entero Therapeutics compare to SoundThinking?

Entero Therapeutics (NASDAQ:GRDX) and SoundThinking (NASDAQ:SSTI) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Entero Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, SoundThinking has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

In the previous week, Entero Therapeutics had 1 more articles in the media than SoundThinking. MarketBeat recorded 2 mentions for Entero Therapeutics and 1 mentions for SoundThinking. SoundThinking's average media sentiment score of 1.89 beat Entero Therapeutics' score of 1.43 indicating that SoundThinking is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Positive
SoundThinking	Very Positive

SoundThinking has a consensus target price of $10.83, indicating a potential upside of 83.00%. Given SoundThinking's stronger consensus rating and higher possible upside, analysts clearly believe SoundThinking is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SoundThinking	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Entero Therapeutics has a net margin of 0.00% compared to SoundThinking's net margin of -16.92%. SoundThinking's return on equity of -23.77% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-47.34%	-16.07%
SoundThinking	-16.92%	-23.77%	-12.90%

Entero Therapeutics has higher earnings, but lower revenue than SoundThinking. SoundThinking is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	538.32	-$6.39M	-$1.90	N/A
SoundThinking	$104.13M	0.74	-$9.42M	-$1.29	N/A

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 60.7% of SoundThinking shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 10.9% of SoundThinking shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

SoundThinking beats Entero Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Entero Therapeutics compare to BTCS?

BTCS (NASDAQ:BTCS) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

BTCS has a beta of 3.38, suggesting that its stock price is 238% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market.

Entero Therapeutics has lower revenue, but higher earnings than BTCS. Entero Therapeutics is trading at a lower price-to-earnings ratio than BTCS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BTCS	$16.49M	4.07	-$33.35M	-$3.31	N/A
Entero Therapeutics	$40K	538.32	-$6.39M	-$1.90	N/A

In the previous week, BTCS had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 4 mentions for BTCS and 2 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.43 beat BTCS's score of 0.75 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BTCS	Positive
Entero Therapeutics	Positive

BTCS presently has a consensus target price of $5.00, suggesting a potential upside of 290.63%. Given BTCS's stronger consensus rating and higher possible upside, equities analysts clearly believe BTCS is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BTCS	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

3.5% of BTCS shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 16.9% of BTCS shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Entero Therapeutics has a net margin of 0.00% compared to BTCS's net margin of -746.29%. BTCS's return on equity of -14.40% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BTCS	-746.29%	-14.40%	-9.21%
Entero Therapeutics	N/A	-47.34%	-16.07%

Summary

BTCS beats Entero Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Entero Therapeutics compare to Airship AI?

Airship AI (NASDAQ:AISP) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Airship AI has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the broader market.

Airship AI presently has a consensus price target of $6.50, suggesting a potential upside of 245.74%. Given Airship AI's stronger consensus rating and higher possible upside, analysts clearly believe Airship AI is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Airship AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Airship AI has a net margin of 144.60% compared to Entero Therapeutics' net margin of 0.00%. Airship AI's return on equity of -19.13% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Airship AI	144.60%	-19.13%	18.72%
Entero Therapeutics	N/A	-47.34%	-16.07%

5.9% of Airship AI shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 46.8% of Airship AI shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Entero Therapeutics had 1 more articles in the media than Airship AI. MarketBeat recorded 2 mentions for Entero Therapeutics and 1 mentions for Airship AI. Airship AI's average media sentiment score of 1.87 beat Entero Therapeutics' score of 1.43 indicating that Airship AI is being referred to more favorably in the media.

Company	Overall Sentiment
Airship AI	Very Positive
Entero Therapeutics	Positive

Airship AI has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Airship AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Airship AI	$15.32M	4.23	$29.32M	$0.67	2.81
Entero Therapeutics	$40K	538.32	-$6.39M	-$1.90	N/A

Summary

Airship AI beats Entero Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRDX vs. The Competition

Export

Metric	Entero Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$21.18M	$15.93B	$29.45B	$14.46B
Dividend Yield	N/A	3.43%	2.75%	12.21%
P/E Ratio	-1.59	141.14	76.28	25.31
Price / Sales	538.32	1,286.97	589.40	87.60
Price / Cash	N/A	46.65	47.48	51.48
Price / Book	0.41	8.65	7.67	6.18
Net Income	-$6.39M	$435.49M	$705.00M	$357.96M
7 Day Performance	-5.63%	-1.19%	-1.90%	-1.61%
1 Month Performance	-27.58%	-1.31%	-4.79%	-3.62%
1 Year Performance	N/A	-0.40%	176.50%	5.95%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRDX Entero Therapeutics	1.5321 of 5 stars	$3.02 +1.7%	N/A	N/A	$21.18M	$40K	N/A	9	Positive News Short Interest Decrease Gap Down
ROC Rank One Computing	2.337 of 5 stars	$4.25 -1.2%	$9.00 +111.8%	N/A	$81.09M	$16.98M	N/A	77
THRY Thryv	2.6413 of 5 stars	$1.79 -2.2%	$8.50 +374.9%	-84.1%	$79.55M	$785.02M	N/A	2,729	News Coverage Positive News
SSTI SoundThinking	3.8109 of 5 stars	$5.61 -0.5%	$10.83 +93.1%	-53.3%	$72.67M	$104.13M	N/A	213	Positive News
BTCS BTCS	3.3373 of 5 stars	$1.32 flat	$5.00 +278.8%	-71.6%	$69.26M	$16.49M	N/A	4	Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRDX) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (GRDX) Competitors

GRDX vs. ROC, THRY, SSTI, BTCS, and AISP

How does Entero Therapeutics compare to Rank One Computing?

Summary

How does Entero Therapeutics compare to Thryv?

Summary

How does Entero Therapeutics compare to SoundThinking?

Summary

How does Entero Therapeutics compare to BTCS?

Summary

How does Entero Therapeutics compare to Airship AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (GRDX) Competitors

GRDX vs. ROC, THRY, SSTI, BTCS, and AISP

How does Entero Therapeutics compare to Rank One Computing?

Do institutionals & insiders believe in GRDX or ROC?

Is GRDX or ROC more profitable?

Does the media favor GRDX or ROC?

Which has better earnings and valuation, GRDX or ROC?

Do analysts rate GRDX or ROC?

Summary

How does Entero Therapeutics compare to Thryv?

Is GRDX or THRY more profitable?

Which has more volatility & risk, GRDX or THRY?

Do institutionals & insiders hold more shares of GRDX or THRY?

Do analysts recommend GRDX or THRY?

Which has better valuation and earnings, GRDX or THRY?

Does the media prefer GRDX or THRY?

Summary

How does Entero Therapeutics compare to SoundThinking?

Which has more volatility and risk, GRDX or SSTI?

Does the media favor GRDX or SSTI?

Do analysts prefer GRDX or SSTI?

Is GRDX or SSTI more profitable?

Which has higher earnings and valuation, GRDX or SSTI?

Do institutionals & insiders have more ownership in GRDX or SSTI?

Summary

How does Entero Therapeutics compare to BTCS?

Which has more volatility and risk, BTCS or GRDX?

Which has higher earnings & valuation, BTCS or GRDX?

Does the media favor BTCS or GRDX?

Do analysts recommend BTCS or GRDX?

Do institutionals and insiders hold more shares of BTCS or GRDX?

Is BTCS or GRDX more profitable?

Summary

How does Entero Therapeutics compare to Airship AI?

Which has more volatility & risk, AISP or GRDX?

Do analysts recommend AISP or GRDX?

Is AISP or GRDX more profitable?

Do institutionals & insiders hold more shares of AISP or GRDX?

Does the media prefer AISP or GRDX?

Which has higher earnings and valuation, AISP or GRDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools